Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.

[1]  M. Mijic,et al.  External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis , 2021, Canadian journal of gastroenterology & hepatology.

[2]  F. Nevens,et al.  A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis , 2021, The American journal of gastroenterology.

[3]  T. Berg,et al.  Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis , 2021, Alimentary pharmacology & therapeutics.

[4]  V. Ronca,et al.  Real-world experience with obeticholic acid in patients with primary biliary cholangitis , 2021, JHEP reports : innovation in hepatology.

[5]  D. Magrez,et al.  A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. , 2021, Journal of hepatology.

[6]  M. Manns,et al.  A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA. , 2020, Journal of hepatology.

[7]  F. Nevens,et al.  Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  F. Nevens,et al.  Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. , 2020, The American journal of gastroenterology.

[9]  T. Masaki,et al.  Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis , 2019, Journal of clinical medicine.

[10]  T. Berg,et al.  Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. , 2019, The American journal of gastroenterology.

[11]  S. Olafsson,et al.  Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study , 2019, Scandinavian journal of gastroenterology.

[12]  J. Boyer,et al.  Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[13]  Y. Kim,et al.  Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio , 2018, Gut and liver.

[14]  Holly F. Ainsworth,et al.  Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. , 2018, The lancet. Gastroenterology & hepatology.

[15]  V. de Lédinghen,et al.  A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis , 2018, The New England journal of medicine.

[16]  M. de Andrade,et al.  External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid , 2018, Hepatology communications.

[17]  F. Nevens,et al.  Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome , 2018, The American Journal of Gastroenterology.

[18]  M. Vergara,et al.  Analysis of predictive response scores to treatment with ursodeoxycholic acid in patients with primary biliary cholangitis. , 2018, Medicina clínica (Ed. impresa).

[19]  E. Rigopoulou,et al.  Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. , 2017, European journal of internal medicine.

[20]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[21]  M. Yuen,et al.  Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid , 2017, Clinical and translational gastroenterology.

[22]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[23]  S. Sharp,et al.  The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis , 2016, Hepatology.

[24]  A. Burroughs,et al.  University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy , 2022 .

[25]  V. Wong,et al.  New simple prognostic score for primary biliary cirrhosis: Albumin‐bilirubin score , 2015, Journal of gastroenterology and hepatology.

[26]  A. Burroughs,et al.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.

[27]  J. Neuberger,et al.  Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. , 2014, Journal of hepatology.

[28]  E. Atkinson,et al.  Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients , 2014, Journal of Gastroenterology.

[29]  B. Liu,et al.  Early biochemical response to ursodeoxycholic acid and long‐term prognosis of primary biliary cirrhosis: Results of a 14‐year cohort study , 2013, Hepatology.

[30]  R. Zhong,et al.  Value of baseline platelet count for prediction of complications in primary biliary cirrhosis patients treated with ursodeoxycholic acid , 2013, Scandinavian journal of clinical and laboratory investigation.

[31]  K. Lindor,et al.  Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[32]  O. Chazouilleres,et al.  Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.

[33]  T. Arenovich,et al.  Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis , 2010, The American Journal of Gastroenterology.

[34]  D. Fenyves,et al.  Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[35]  D. Moher,et al.  Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Physical therapy.

[36]  Y. Hiasa,et al.  Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis , 2009, Journal of Gastroenterology.

[37]  K. V. van Erpecum,et al.  Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. , 2009, Gastroenterology.

[38]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[39]  E. Christensen,et al.  Ursodeoxycholic Acid for Patients With Primary Biliary Cirrhosis: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials Using Bayesian Approach as Sensitivity Analyses , 2007, The American Journal of Gastroenterology.

[40]  Paul A. Fontelo,et al.  Utilization of the PICO framework to improve searching PubMed for clinical questions , 2007, BMC Medical Informatics Decis. Mak..

[41]  B. Hansen,et al.  Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients , 2006, The American Journal of Gastroenterology.

[42]  J. Rodés,et al.  Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.

[43]  T. Therneau,et al.  Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. , 1999, Liver.

[44]  E. Dickson,et al.  Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. , 1995, Gut.

[45]  P. Grambsch,et al.  Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.

[46]  D. Altman,et al.  Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. , 1985, Gastroenterology.

[47]  J. Boyer,et al.  The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. , 1983, The New England journal of medicine.